Cargando…

Video‐assisted thoracoscopic surgery lobectomy might be a feasible alternative for surgically resectable pathological N2 non‐small cell lung cancer patients

BACKGROUND: The majority of previous studies of the clinical outcome of video‐assisted thoracoscopic surgery (VATS) versus open lobectomy for pathological N2 non‐small cell lung cancer (pN2 NSCLC) have been single‐center experiences with small patient numbers. The aim of this study was therefore to...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Jinbo, Li, Weimiao, Wang, Meng, Liu, Lunxu, Fu, Xiangning, Li, Yin, Xu, Lin, Liu, Yang, Zhao, Heng, Hu, Jian, Liu, Deruo, Shen, Jianfei, Yang, Haiying, Li, Xiaofei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779187/
https://www.ncbi.nlm.nih.gov/pubmed/33205914
http://dx.doi.org/10.1111/1759-7714.13680
_version_ 1783631283813875712
author Zhao, Jinbo
Li, Weimiao
Wang, Meng
Liu, Lunxu
Fu, Xiangning
Li, Yin
Xu, Lin
Liu, Yang
Zhao, Heng
Hu, Jian
Liu, Deruo
Shen, Jianfei
Yang, Haiying
Li, Xiaofei
author_facet Zhao, Jinbo
Li, Weimiao
Wang, Meng
Liu, Lunxu
Fu, Xiangning
Li, Yin
Xu, Lin
Liu, Yang
Zhao, Heng
Hu, Jian
Liu, Deruo
Shen, Jianfei
Yang, Haiying
Li, Xiaofei
author_sort Zhao, Jinbo
collection PubMed
description BACKGROUND: The majority of previous studies of the clinical outcome of video‐assisted thoracoscopic surgery (VATS) versus open lobectomy for pathological N2 non‐small cell lung cancer (pN2 NSCLC) have been single‐center experiences with small patient numbers. The aim of this study was therefore to investigate these procedures but in a large cohort of Chinese patients with pathological N2 NSCLC in real‐world conditions. METHODS: Patients who underwent lobectomy for pN2 NSCLC by either VATS or thoracotomy were retrospectively reviewed from 10 tertiary hospitals between January 2014 and September 2017. Perioperative outcomes and overall survival of the patients were analyzed. Cox regression analysis was performed to identify potential prognostic factors. Propensity‐score analysis was performed to reduce cofounding biases and compare the clinical outcomes between both groups. RESULTS: Among 2144 pN2 NSCLC, 1244 patients were managed by VATS and 900 by open procedure. A total of 305 (24.5%) and 344 patients died during VATS and the thoracotomy group during a median follow‐up of 16.7 and 15.6 months, respectively. VATS lobectomy patients had better overall survival when compared with those undergoing the open procedure (P < 0.0001). Multivariate COX regression analysis showed VATS lobectomy independently favored overall survival (HR = 0.75, 95% CI: 0.621–0.896, P = 0.0017). Better perioperative outcomes, including less blood loss, shorter drainage time and hospital stay, were also observed in patients undergoing VATS lobectomy (P < 0.05). After propensity‐score matching, 169 patients in each group were analyzed, and no survival difference were found between the two groups. Less blood loss was observed in the VATS group, but there was a longer operation time. CONCLUSIONS: VATS lobectomy might be a feasible alternative to conventional open surgery for resectable pN2 NSCLC. KEY POINTS: Significant findings of the study: VATS lobectomy has comparative OS in pN2 NSCLC versus open procedure in resectable patients. What this study adds: VATS lobectomy might be feasible for pN2 NSCLC.
format Online
Article
Text
id pubmed-7779187
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-77791872021-01-08 Video‐assisted thoracoscopic surgery lobectomy might be a feasible alternative for surgically resectable pathological N2 non‐small cell lung cancer patients Zhao, Jinbo Li, Weimiao Wang, Meng Liu, Lunxu Fu, Xiangning Li, Yin Xu, Lin Liu, Yang Zhao, Heng Hu, Jian Liu, Deruo Shen, Jianfei Yang, Haiying Li, Xiaofei Thorac Cancer Original Articles BACKGROUND: The majority of previous studies of the clinical outcome of video‐assisted thoracoscopic surgery (VATS) versus open lobectomy for pathological N2 non‐small cell lung cancer (pN2 NSCLC) have been single‐center experiences with small patient numbers. The aim of this study was therefore to investigate these procedures but in a large cohort of Chinese patients with pathological N2 NSCLC in real‐world conditions. METHODS: Patients who underwent lobectomy for pN2 NSCLC by either VATS or thoracotomy were retrospectively reviewed from 10 tertiary hospitals between January 2014 and September 2017. Perioperative outcomes and overall survival of the patients were analyzed. Cox regression analysis was performed to identify potential prognostic factors. Propensity‐score analysis was performed to reduce cofounding biases and compare the clinical outcomes between both groups. RESULTS: Among 2144 pN2 NSCLC, 1244 patients were managed by VATS and 900 by open procedure. A total of 305 (24.5%) and 344 patients died during VATS and the thoracotomy group during a median follow‐up of 16.7 and 15.6 months, respectively. VATS lobectomy patients had better overall survival when compared with those undergoing the open procedure (P < 0.0001). Multivariate COX regression analysis showed VATS lobectomy independently favored overall survival (HR = 0.75, 95% CI: 0.621–0.896, P = 0.0017). Better perioperative outcomes, including less blood loss, shorter drainage time and hospital stay, were also observed in patients undergoing VATS lobectomy (P < 0.05). After propensity‐score matching, 169 patients in each group were analyzed, and no survival difference were found between the two groups. Less blood loss was observed in the VATS group, but there was a longer operation time. CONCLUSIONS: VATS lobectomy might be a feasible alternative to conventional open surgery for resectable pN2 NSCLC. KEY POINTS: Significant findings of the study: VATS lobectomy has comparative OS in pN2 NSCLC versus open procedure in resectable patients. What this study adds: VATS lobectomy might be feasible for pN2 NSCLC. John Wiley & Sons Australia, Ltd 2020-11-18 2021-01 /pmc/articles/PMC7779187/ /pubmed/33205914 http://dx.doi.org/10.1111/1759-7714.13680 Text en © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Zhao, Jinbo
Li, Weimiao
Wang, Meng
Liu, Lunxu
Fu, Xiangning
Li, Yin
Xu, Lin
Liu, Yang
Zhao, Heng
Hu, Jian
Liu, Deruo
Shen, Jianfei
Yang, Haiying
Li, Xiaofei
Video‐assisted thoracoscopic surgery lobectomy might be a feasible alternative for surgically resectable pathological N2 non‐small cell lung cancer patients
title Video‐assisted thoracoscopic surgery lobectomy might be a feasible alternative for surgically resectable pathological N2 non‐small cell lung cancer patients
title_full Video‐assisted thoracoscopic surgery lobectomy might be a feasible alternative for surgically resectable pathological N2 non‐small cell lung cancer patients
title_fullStr Video‐assisted thoracoscopic surgery lobectomy might be a feasible alternative for surgically resectable pathological N2 non‐small cell lung cancer patients
title_full_unstemmed Video‐assisted thoracoscopic surgery lobectomy might be a feasible alternative for surgically resectable pathological N2 non‐small cell lung cancer patients
title_short Video‐assisted thoracoscopic surgery lobectomy might be a feasible alternative for surgically resectable pathological N2 non‐small cell lung cancer patients
title_sort video‐assisted thoracoscopic surgery lobectomy might be a feasible alternative for surgically resectable pathological n2 non‐small cell lung cancer patients
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779187/
https://www.ncbi.nlm.nih.gov/pubmed/33205914
http://dx.doi.org/10.1111/1759-7714.13680
work_keys_str_mv AT zhaojinbo videoassistedthoracoscopicsurgerylobectomymightbeafeasiblealternativeforsurgicallyresectablepathologicaln2nonsmallcelllungcancerpatients
AT liweimiao videoassistedthoracoscopicsurgerylobectomymightbeafeasiblealternativeforsurgicallyresectablepathologicaln2nonsmallcelllungcancerpatients
AT wangmeng videoassistedthoracoscopicsurgerylobectomymightbeafeasiblealternativeforsurgicallyresectablepathologicaln2nonsmallcelllungcancerpatients
AT liulunxu videoassistedthoracoscopicsurgerylobectomymightbeafeasiblealternativeforsurgicallyresectablepathologicaln2nonsmallcelllungcancerpatients
AT fuxiangning videoassistedthoracoscopicsurgerylobectomymightbeafeasiblealternativeforsurgicallyresectablepathologicaln2nonsmallcelllungcancerpatients
AT liyin videoassistedthoracoscopicsurgerylobectomymightbeafeasiblealternativeforsurgicallyresectablepathologicaln2nonsmallcelllungcancerpatients
AT xulin videoassistedthoracoscopicsurgerylobectomymightbeafeasiblealternativeforsurgicallyresectablepathologicaln2nonsmallcelllungcancerpatients
AT liuyang videoassistedthoracoscopicsurgerylobectomymightbeafeasiblealternativeforsurgicallyresectablepathologicaln2nonsmallcelllungcancerpatients
AT zhaoheng videoassistedthoracoscopicsurgerylobectomymightbeafeasiblealternativeforsurgicallyresectablepathologicaln2nonsmallcelllungcancerpatients
AT hujian videoassistedthoracoscopicsurgerylobectomymightbeafeasiblealternativeforsurgicallyresectablepathologicaln2nonsmallcelllungcancerpatients
AT liuderuo videoassistedthoracoscopicsurgerylobectomymightbeafeasiblealternativeforsurgicallyresectablepathologicaln2nonsmallcelllungcancerpatients
AT shenjianfei videoassistedthoracoscopicsurgerylobectomymightbeafeasiblealternativeforsurgicallyresectablepathologicaln2nonsmallcelllungcancerpatients
AT yanghaiying videoassistedthoracoscopicsurgerylobectomymightbeafeasiblealternativeforsurgicallyresectablepathologicaln2nonsmallcelllungcancerpatients
AT lixiaofei videoassistedthoracoscopicsurgerylobectomymightbeafeasiblealternativeforsurgicallyresectablepathologicaln2nonsmallcelllungcancerpatients